Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$6.81 USD
-0.40 (-5.55%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $6.80 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DAWN 6.81 -0.40(-5.55%)
Will DAWN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DAWN
Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Other News for DAWN
Is DAWN likely to continue lower? Fell Below 50 Day Moving Average shows up after tumbling 5.55%
NR7 appears for DAWN after 3.15% move
DAWN forms Bollinger Band Squeeze on September 18
DAWN forms Bollinger Band Squeeze on September 16
Is DAWN ready to move higher? Non-ADX 1,2,3,4 Bullish shows up after rising 0.84%